company background image
EFTR logo

eFFECTOR Therapeutics OTCPK:EFTR Stock Report

Last Price

US$0.0002

Market Cap

US$940.0

7D

0%

1Y

-100.0%

Updated

24 Nov, 2024

Data

Company Financials

eFFECTOR Therapeutics, Inc.

OTCPK:EFTR Stock Report

Market Cap: US$940.0

EFTR Stock Overview

A biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. More details

EFTR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

eFFECTOR Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for eFFECTOR Therapeutics
Historical stock prices
Current Share PriceUS$0.0002
52 Week HighUS$17.75
52 Week LowUS$0.0001
Beta0.80
11 Month Change100.00%
3 Month Change-99.58%
1 Year Change-100.00%
33 Year Change-100.00%
5 Year Changen/a
Change since IPO-100.00%

Recent News & Updates

Recent updates

eFFECTOR doses first patient in second cohort of phase 1b trial of potential COVID drug

Sep 14

eFFECTOR Therapeutics GAAP EPS of -$0.17

Aug 09

eFFECTOR: Developing New Class Of Cancer Therapies

Sep 12

Shareholder Returns

EFTRUS BiotechsUS Market
7D0%2.5%2.2%
1Y-100.0%16.1%31.6%

Return vs Industry: EFTR underperformed the US Biotechs industry which returned 16.2% over the past year.

Return vs Market: EFTR underperformed the US Market which returned 31.7% over the past year.

Price Volatility

Is EFTR's price volatile compared to industry and market?
EFTR volatility
EFTR Average Weekly Movement77.4%
Biotechs Industry Average Movement9.8%
Market Average Movement6.3%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: EFTR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: EFTR's weekly volatility has increased from 47% to 77% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201214Craig Jalberteffector.com

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company’s lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer.

eFFECTOR Therapeutics, Inc. Fundamentals Summary

How do eFFECTOR Therapeutics's earnings and revenue compare to its market cap?
EFTR fundamental statistics
Market capUS$940.00
Earnings (TTM)-US$34.63m
Revenue (TTM)n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EFTR income statement (TTM)
RevenueUS$0
Cost of RevenueUS$21.62m
Gross Profit-US$21.62m
Other ExpensesUS$13.02m
Earnings-US$34.63m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-7.36
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio2,420.3%

How did EFTR perform over the long term?

See historical performance and comparison